We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Breast Cancer Recurrence Risk Predicted by Immune-Related Germline Variants

By LabMedica International staff writers
Posted on 25 Nov 2019
Print article
Image: The Oncotype DX test is a genomic test that analyzes the activity of a group of genes that can affect how a cancer is likely to behave and respond to treatment (Photo courtesy of Michael Jarrett/Genomic Health)
Image: The Oncotype DX test is a genomic test that analyzes the activity of a group of genes that can affect how a cancer is likely to behave and respond to treatment (Photo courtesy of Michael Jarrett/Genomic Health)
A single normal cell randomly acquires a series of mutations that allows it to proliferate and to be transformed into a cancer cell (i.e., founding clone), which initiates tumor progression and recurrence.

Pre-existing germline variants provide a profound constraint on the evolution of tumor founding clones and subclones and therefore have a contingent effect on the genetic makeup of tumor and presumably patient outcomes. Family history remains one of the major risk factors that contribute to cancer.

Scientists from the University of Calgary (Calgary, AB, Canada) and their colleagues obtained whole-exome sequencing data of breast cancers from the National Cancer Institute-Genomic Data Commons (NCI GDC). They collected 755 ER+ breast cancer samples: a training set of 200 samples, a testing set of 60 samples, and two independent validation sets of 200 and 295 samples. To determine germline variants, they used variant allele frequencies (VAFs) between the tumor and healthy samples. The team used their so-called eTumorMetastasis algorithm to search for germline signatures of recurrence based on protein-coding sequences.

The scientists used the eTumorMetastasis tool, which combines variant, signaling, and network information, and initially tracked down 18 network operational gene (NOG) signatures, each containing variants involving dozens of genes. When they combined these signatures, the investigators came up with a unified germline gene set that appeared to coincide with recurrence in 60 more ER-positive breast tumors. In those validation cohorts, the authors reported, "germline variants are significantly correlated with tumor recurrence and support their hypothesis that the original germline genomic landscape of a cancer patient has a significant impact on clinical outcome."

The investigators noted that the germline variant-based prediction strategy compared favorably with prognostic insights that could be gleaned from the Oncotype DX test (Genomic Health, Redwood City, CA, USA) which considers expression levels for 21 genes in biopsied or surgically-removed tumor samples. They found that recurred patients possessed a higher rate of germline variants. In addition, the inherited germline variants from these gene signatures were predominately enriched in T cell function, antigen presentation, and cytokine interactions, likely impairing the adaptive and innate immune response thus favoring a pro-tumorigenic environment.

Edwin Wang, PhD, a professor and senior author of the study, said, “Prognostic prediction using a patient's germline genomic landscape opens up the possibility of assessing cancer patients' risk of recurrence, which allows for a better forecasting of cancer recurrence in a quick, convenient, and noninvasive manner.” The authors concluded that germline genomic information could be used for developing non-invasive genomic tests for predicting patients’ outcomes in breast cancer. The study was published on November 1, 2019 in the journal NPJ Precision Oncology.

Related Links:
University of Calgary
Genomic Health


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.